BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shafran SD. HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials. Clin Infect Dis 2015;61:1127-34. [DOI: 10.1093/cid/civ438] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Tempestilli M, Fabbri G, Mastrorosa I, Timelli L, Notari S, Bellagamba R, Libertone R, Lupi F, Zaccarelli M, Antinori A, Agrati C, Ammassari A. Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world. J Antimicrob Chemother 2018;73:160-4. [PMID: 29106584 DOI: 10.1093/jac/dkx348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Alam I, Brown K, Donovan C, Forlenza J, Lauwers K, Mah'moud MA, Manch R, Mohanty SR, Prabhakar A, Reindollar R, DeMasi R, Slim J, Tandon N, Villadiego S, Naggie S. Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study. Open Forum Infect Dis 2017;4:ofw258. [PMID: 28480251 DOI: 10.1093/ofid/ofw258] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
3 Puhr R, Wright ST, Hoy JF, Templeton DJ, Durier N, Matthews GV, Russell D, Law MG. Retrospective study of hepatitis C outcomes and treatment in HIV co-infected persons from the Australian HIV Observational Database. Sex Health 2017;14:345-54. [PMID: 28482168 DOI: 10.1071/SH16151] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Cachay ER, Wyles D, Hill L, Ballard C, Torriani F, Colwell B, Kuo A, Schooley R, Mathews CW. The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care. Open Forum Infect Dis 2015;2:ofv168. [PMID: 26697509 DOI: 10.1093/ofid/ofv168] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
5 Casey JL, Feld JJ, MacParland SA. Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection. Cells 2019;8:E317. [PMID: 30959825 DOI: 10.3390/cells8040317] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
6 Bischoff J, Mauss S, Cordes C, Lutz T, Scholten S, Moll A, Jäger H, Cornberg M, Manns MP, Baumgarten A, Rockstroh JK. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? HIV Med 2018;19:299-307. [PMID: 29368456 DOI: 10.1111/hiv.12579] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
7 Puoti M, Lorenzini P, Cozzi-lepri A, Gori A, Mastroianni C, Rizzardini G, Mazzarello G, Antinori A, d'Arminio Monforte A, Girardi E, d’Arminio Monforte A, Andreoni M, Angarano G, Antinori A, Castelli F, Cauda R, Di Perri G, Galli M, Iardino R, Ippolito G, Lazzarin A, Perno C, von Schloesser F, Viale P, Castagna A, Ceccherini-silberstein F, Cozzi-lepri A, Girardi E, Lo Caputo S, Mussini C, Puoti M, Andreoni M, Ammassari A, Balotta C, Bandera A, Bonfanti P, Bonora S, Borderi M, Calcagno A, Calza L, Capobianchi M, Castagna A, Ceccherini-silberstein F, Cingolani A, Cinque P, De Luca A, Di Biagio A, Gianotti N, Gori A, Guaraldi G, Lapadula G, Lichtner M, Lo Caputo S, Madeddu G, Maggiolo F, Marchetti G, Marcotullio S, Monno L, Mussini C, Nozza S, Quiros Roldan E, Rossotti R, Rusconi S, Santoro M, Saracino A, Zaccarelli M, Fanti I, Galli L, Lorenzini P, Rodano A, Shanyinde M, Tavelli A, Carletti F, Carrara S, Di Caro A, Graziano S, Petrone F, Prota G, Quartu S, Truffa S, Giacometti IA, Costantini A, Valeriani C, Angarano G, Monno L, Santoro C, Maggiolo F, Suardi C, Viale P, Donati V, Verucchi G, Castelli F, Quiros Roldan E, Minardi C, Quirino T, Abeli C, Manconi P, Piano P, Cacopardo B, Celesia B, Vecchiet J, Falasca K, Sighinolfi L, Segala D, Mazzotta F, Vichi F, Cassola G, Viscoli C, Alessandrini A, Bobbio N, Mazzarello G, Mastroianni C, Belvisi V, Bonfanti P, Caramma I, Chiodera A, Castelli A, Galli M, Lazzarin A, Rizzardini G, Ridolfo A, Piolini R, Castagna A, Salpietro S, Carenzi L, Moioli M, Tincati C, Marchetti G, Mussini C, Puzzolante C, Lapadula G, Abrescia N, Chirianni A, Borgia G, Di Martino F, Maddaloni L, Gentile I, Orlando R, Baldelli F, Francisci D, Parruti G, Ursini T, Magnani G, Ursitti M, Cauda R, Andreoni M, Vullo V, Cristaudo A, Cingolani A, Baldin G, Cicalini S, Gallo L, Nicastri E, Acinapura R, Capozzi M, Libertone R, Savinelli S, Latini A, Iaiani G, Fontanelli Sulekova L, Cecchetto M, Viviani F, Mura M, Madeddu G, De Luca A, Rossetti B, Caramello P, Di Perri G, Orofino G, Bonora S, Sciandra M, Bassetti M, Londero A, Pellizzer G, Manfrin V. Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. Clinical Microbiology and Infection 2017;23:267.e1-4. [DOI: 10.1016/j.cmi.2016.12.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
8 Llaneras J, Castells L, Santos B, Crespo M, Puig T, Esteban J, Esteban R. Removal from liver transplantation list of a hepatitis C virus-HIV co-infected patient after successful treatment with sofosbuvir and daclatasvir. Transpl Infect Dis 2016;18:442-5. [DOI: 10.1111/tid.12538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Meissner EG. Update in HIV-hepatitis C virus coinfection in the direct acting antiviral era. Curr Opin Gastroenterol 2017;33:120-7. [PMID: 28234770 DOI: 10.1097/MOG.0000000000000347] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
10 Uriarte-Pinto M, Navarro-Aznarez H, De La Llama-Celis N, Arazo-Garcés P, Martínez-Sapiña AM, Abad-Sazatornil MR. Effectiveness and security of chronic hepatitis C treatment in coinfected patients in real-world. Int J Clin Pharm 2018;40:608-16. [PMID: 29556931 DOI: 10.1007/s11096-018-0621-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Ogbuagu O, Hao R, Virata M, Villanueva MS, Malinis M. Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients. F1000Res 2017;6:620. [PMID: 30344999 DOI: 10.12688/f1000research.11397.2] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Gountas I, Sypsa V, Anagnostou O, Martin N, Vickerman P, Kafetzopoulos E, Hatzakis A. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting? Addiction 2017;112:1290-9. [PMID: 28107585 DOI: 10.1111/add.13764] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
13 Fernández-Montero JV, Soriano V. SOLAR-2: the sun also rises for cirrhotics. Lancet Infect Dis 2016;16:624-5. [PMID: 26907737 DOI: 10.1016/S1473-3099(16)00079-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
14 Gountas I, Sypsa V, Blach S, Razavi H, Hatzakis A. HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era. PLoS One. 2018;13:e0202109. [PMID: 30114207 DOI: 10.1371/journal.pone.0202109] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
15 Castells L, Llaneras J, Campos-Varela I, Bilbao I, Crespo M, Len O, Rodríguez-Frías F, Charco R, Salcedo T, Esteban JI, Esteban-Mur R.  Sofosbuvir and daclatasvir in mono- and HIV-coinfected patients with recurrent hepatitis C after liver transplant. Ann Hepatol 2017;16:86-93. [PMID: 28051797 DOI: 10.5604/16652681.1226819] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
16 Neukam K, Morano-amado LE, Rivero-juárez A, Mancebo M, Granados R, Téllez F, Collado A, Ríos MJ, de los Santos-gil I, Reus-bañuls S, Vera-méndez F, Geijo-martínez P, Montero-alonso M, Suárez-santamaría M, Pineda JA. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study. HIV Clinical Trials 2017;18:126-34. [DOI: 10.1080/15284336.2017.1330801] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
17 Buchacz K, Armon C, Palella FJ Jr, Novak RM, Fuhrer J, Tedaldi E, Ward D, Mayer C, Battalora L, Carlson K, Purinton S, Durham M, Li J; HIV Outpatient Study (HOPS) Investigators . The HIV Outpatient Study-25 Years of HIV Patient Care and Epidemiologic Research. Open Forum Infect Dis 2020;7:ofaa123. [PMID: 32455145 DOI: 10.1093/ofid/ofaa123] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
18 Lee TH, Chan A, Bryan W, Park L, Hashem M, Townsend M, Moylan C, Britt R, Choi S, Naggie S. Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort. J Viral Hepat 2021;28:630-6. [PMID: 33378562 DOI: 10.1111/jvh.13462] [Reference Citation Analysis]
19 Zheng YX, Ma SJ, Xiong YH, Fan XG. Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis. J Gastroenterol Hepatol 2020;35:1477-87. [PMID: 32246857 DOI: 10.1111/jgh.15051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
20 Chan DP, Sun H, Wong HT, Lee S, Hung C. Sexually acquired hepatitis C virus infection: a review. International Journal of Infectious Diseases 2016;49:47-58. [DOI: 10.1016/j.ijid.2016.05.030] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 12.3] [Reference Citation Analysis]
21 Puri P, Saraswat VA, Dhiman RK, Anand AC, Acharya SK, Singh SP, Chawla YK, Amarapurkar DN, Kumar A, Arora A, Dixit VK, Koshy A, Sood A, Duseja A, Kapoor D, Madan K, Srivastava A, Kumar A, Wadhawan M, Goel A, Verma A, Shalimar, Pandey G, Malik R, Agrawal S. Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016. J Clin Exp Hepatol 2016;6:119-45. [PMID: 27493460 DOI: 10.1016/j.jceh.2016.07.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
22 Shumway M, Luetkemeyer AF, Peters MG, Johnson MO, Napoles TM, Riley ED. Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences. AIDS Care 2019;31:1340-7. [PMID: 30829533 DOI: 10.1080/09540121.2019.1587353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Menard A, Colson P, Catherine D, Isabelle R, Christelle T, Meddeb L, Ben Ali S, Solas C, Stein A. First Real Life Evidence of New Direct-acting Antivirals (DAA) in Co-infected HIV HCV Patients: Better than Ever. Clin Infect Dis 2016;62:947-9. [PMID: 26740514 DOI: 10.1093/cid/civ1215] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]